Legend Biotech Corporation (LEGN)

Basic

  • Market Cap

    $11.91B

  • EV

    $10.81B

  • Shares Out

    181.79M

  • Revenue

    $233.31M

  • Employees

    1,700

Margins

  • Gross

    -110.88%

  • EBITDA

    -188.29%

  • Operating

    -192.77%

  • Pre-Tax

    -218.18%

  • Net

    -218.3%

  • FCF

    -158.44%

Returns (5Yr Avg)

  • ROA

    -20.84%

  • ROTA

    -68.93%

  • ROE

    -68.64%

  • ROCE

    -44.12%

  • ROIC

    -100.02%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $86.02

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $1,423.84M

  • Net Debt

    -$1,103.33M

  • Debt/Equity

    0.24

  • EBIT/Interest

    -21.59

Growth (CAGR)

  • Rev 3Yr

    58.42%

  • Rev 5Yr

    37.63%

  • Rev 10Yr

  • Dil EPS 3Yr

    1.74%

  • Dil EPS 5Yr

    130.86%

  • Dil EPS 10Yr

  • Rev Fwd 2Yr

    123.63%

  • EBITDA Fwd 2Yr

  • EPS Fwd 2Yr

  • EPS LT Growth Est

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

Select a metric from the list below to chart it

Dec '17

Dec '18

Jan '20

Dec '20

Dec '21

Dec '22

LTM

Revenues

49.1

60

75

65.4

116.7

233

Other Revenues, Total

0.4

1.8

3.4

0.3

0.3

Total Revenues

49.5

61.8

75

68.8

117

233.3

Total Revenues % Chg.

108.9%

24.9%

21.4%

-8.2%

70%

120.3%

Cost of Goods Sold, Total

232.2

313.3

401

492

Gross Profit

49.5

61.8

-157.2

-244.5

-284

-258.7

Selling General & Admin Expenses, Total

3.9

32.4

72.7

149.5

174

191

R&D Expenses

60.6

161.9

Other Operating Expenses, Total

64.6

194.3

72.7

149.5

174

191

Operating Income

-15.1

-132.5

-229.9

-394

-458.1

-449.8

Interest Expense, Total

-0.1

-0.2

-0.2

-0.9

-10.8

-20.8

Interest And Investment Income

6.2

4.6

2.9

1

8.2

42.1

Net Interest Expenses

6.1

4.4

2.7

0.1

-2.6

21.2

Currency Exchange Gains (Loss)

7.2

0.6

0.1

10.1

Other Non Operating Income (Expenses)

-0

-0.2

-1.2

-12.3

14.8

-91.5

EBT, Excl. Unusual Items

-1.7

-127.8

-228.3

-406.2

-445.8

-509.8

Gain (Loss) On Sale Of Investments

0.1

0.5

0

0.6

1.3

Gain (Loss) On Sale Of Assets

-0.1

-1

-0.5

-0.5

Other Unusual Items

-80

EBT, Incl. Unusual Items

-1.6

-127.3

-308.3

-407.2

-445.7

-509

Income Tax Expense

1.2

-25.7

-41.9

-3.6

0.6

0.3

Earnings From Continuing Operations

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Net Income

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Net Income to Common Incl Extra Items

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Net Income to Common Excl. Extra Items

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Total Shares Outstanding

100

100

133

154.2

165.1

181.8

Weighted Avg. Shares Outstanding

100

100

118.2

140.9

159

171.9

Weighted Avg. Shares Outstanding Dil

100

100

118.2

140.9

159

171.9

EPS

-0

-1

-2.3

-2.9

-2.8

-3

EPS Diluted

-0

-1

-2.3

-2.9

-2.8

-3

EBITDA

-14.2

-129.4

-223.6

-385.9

-447.9

-439.3